Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.

T. Y. Chao, H. Ohnishi, T. M. Chu

研究成果: 雜誌貢獻文章同行評審

5 引文 斯高帕斯(Scopus)


The effect of indomethacin on murine lymphokine-activated killer (LAK) cell activity was investigated using a natural killer-resistant, spontaneously developed, weakly immunogenic, and highly tumorigenic syngeneic murine mammary adenocarcinoma, mimicking that of human disease, as the target. When used in combination with human recombinant interleukin-2 (rIL-2), indomethacin was found to augment LAK cell activity, which was generated from culture of the normal mouse splenocytes with rIL-2, as compared to that with rIL-2 alone. This increase in LAK cell activity was shown to be indomethacin dose-dependent, and was demonstrated only when indomethacin was added to the rIL-2-containing medium at the beginning of culture. The enhancement of LAK cell activity by indomethacin was abrogated when the nylon-wool nonadherent "macrophage-poor" splenocytes were incubated with rIL-2 plus indomethacin. These results indicated that the rIL-2-induced LAK cell activity generated from murine splenocytes could be augmented by indomethacin, and the macrophages may be involved as the mediator.

頁(從 - 到)318-322
期刊Molecular biotherapy
出版狀態已發佈 - 1989


深入研究「Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.」主題。共同形成了獨特的指紋。